Neuroendocrine tumours trials in Netherlands

In Netherlands 13 Also abroad 243

13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Utrecht
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 2/3Taking people
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Where
Amsterdam, Maastricht, Veldhoven
Age
18 years and over
People
440 worldwide
Run by
Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00
Phase 3Taking people
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Where
Amsterdam, Groningen, Maastricht, Rotterdam
Age
18 years and over
People
390 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07544654 · EU 2025-523869-22-00
Phase 1/2Not yet taking people in Netherlands
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Amsterdam
Age
18 years and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00
Phase 1Taking people
A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
Where
Amsterdam
Age
18 years and over
People
12
Run by
Boehringer Ingelheim
See details and how to joinNCT05963867
Phase 3Taking people
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Where
Amsterdam, Maastricht, Zwolle
Age
18 years and over
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 · EU 2025-524160-38-00
Phase 3Taking people
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Where
Rotterdam, Utrecht
Age
12 years to 100 years
People
240 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00
Phase 3Taking people
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Groningen, Maastricht, Rotterdam
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00 · EU 2024-520050-38-00
Phase 4Taking people
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial
Where
Amsterdam
Age
18 years and over
People
34
Run by
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
See details and how to join2023-505884-35-00 · EU 2023-505884-35-00
Phase 1Taking people
A study to test how BI 764532 is taken up by tumours in people with small-cell lung cancer or neuroendocrine cancer
Where
Amsterdam
Age
18 years and over
People
12
Run by
Boehringer Ingelheim International GmbH
See details and how to join2022-501818-54-00 · EU 2022-501818-54-00
Phase 1Taking people
Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
Where
Rotterdam
Age
18 years and over
People
24
Run by
Erasmus Medical Center
See details and how to joinNCT05870423
Phase 2/3Taking people
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
Where
Amsterdam
Age
18 years and over
People
39
Run by
The Netherlands Cancer Institute
See details and how to joinNCT06855095
Phase 4Taking people
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
Where
Amsterdam, Arnhem, Eindhoven, Groningen, Maastricht, Rotterdam
Age
18 years and over
People
270 worldwide
Run by
University Hospital, Antwerp
See details and how to joinNCT05701241